Introduction
============

*Acinetobacter baumannii* is the most clinically important species in the Acinetobacter genus that is involved in 1-2% of nosocomial pneumonia primarily in debilitated patients ([@B1], [@B2]). Infections due to *A. baumannii*, especially multi drug resistant strains, have been reported worldwide, so that only a few antibiotics have remained effective against MDR strains.

Resistance against aminopenicillins, ureidop-enicillins, cephalosporins, cephamycins, aminoglyc-osides, chloramphenicol, tetracyclines, fluoroquinol-ones and carbapenems were initially reported from different parts of the world ([@B2]). Tetracycline is a bacteriostatic antibiotic which inhibits protein synthesis by preventing the attachment of aminoacyl-tRNA to the ribosomal acceptor site. To date, the main mechanisms responsible for tetracycline resistance have been identified as (i) expression of efflux pumps and (ii) ribosomal protection. *tet*A and *tet*B are the most extensively characterized genes responsible for ribosomal protection. Although the distribution of many genes responsible for resistance towards antimicrobial agents especially carbapenems and aminoglycosides, has been previously reported among *A. baumannii* isolates in Iran ([@B3]-[@B12]).

There appears to be no comprehensive data concerning the mechanisms of resistance towards tetracycline and related antibiotics among *A. baumannii* isolates in this country. The aim of the present study was, therefore, to analyze the molecular mechanisms of resistance towards tetracycline and related antibiotics among clinical isolates of *A. baumannii* and to estimate the prevalence of the genetic constructs containing *tet*A and *tet*B genes in the isolates of this microorganism. Furthermore, the susceptibility of the isolates towards tigecycline (as a glycylcycline and a derivative of minocycline) and tetracyclines including tetracycline, minocycline and doxicycline was surveyed in this study.

Materials and Methods
=====================

***Study population***

A total of 100 non-repetitive *A. baumannii* isolates were recovered in years 2010 and 2011 from patients in different hospitals of Tehran, Iran. The isolates were non-repetitive, meaning that each isolate was obtained from a particular patient and each patient was sampled only once. These isolates were cultured from wounds (n = 40), the trachea (n = 30), blood (n = 10), urine (n = 15), andcatheter (n = 5). Strains were isolated mainly from patients in intensive care units (n = 36), burned ward (n = 30), internal ward (n = 20) and surgery (n = 4) from eight hospitals in Tehran, Iran.

All the isolates were identified as *A. baumannii* by the detection of *bla*~OXA-51-like~, an intrinsic and species specific gene, using API 20NE and biochemical testing according to those reported in previous reports ([@B13]).

***Antimicrobial susceptibility***

Using E-test, the susceptibility of all the isolates toward tetracycline, minocycline, doxicycline and tigecycline was tested. The isolates were then interpreted according to the manufacturer instructions and CLSI guidelines ([@B14]). *Escherichia coli*, ATCC 25922 and *Pseudomonas aeruginosa,*ATCC 27852 were used as internal control. MIC interpretative standards for together tetracycline, minocycline and doxicycline was S: ≤ 4μg/ml, I: 8 μg/ml and R: ≥16 μg/ml, respectively. The criteria defined by the US Food and Drug Administration (FDA) for Enterobacteriaceae were used for tigecycline (≤2, ≥4 μg/ml for susceptible and non susceptible strains, respectively) ([@B15]).

***DNA extraction***

Strains were maintained at -70°C in 80% /20% (v/v) glycerol in LB medium to preserve genetic variation during storage and were grown overnight on MacConkey agar at 37°C. DNA extraction was carried out by DNA Extraction kit (BIONER, Republic of Korea) in accordance with the manufacturer instructions. DNA was stored at -20°C until further use.

***PCR amplification of tet A and tet B genes***

The PCR products for *tet A* and *tet*B genes were considered presumptive positive based on amplicon sizes of 164bp and 206 bp, respectively. In the case of a negative PCR, PCR amplifications were repeated at least twice for these genes. A negative control was run along each PCR.

The primer sequences included *tet A* (F: 5\'-GCG CGATCTGGTTCACTCG-3\'; R: 5\'-AGTCGACAGYRGCG CCGGC-3\') and *tet B* (F: 5\'- CGTGAATTTATTGCTT CGG-3\'; R: 5\'-ATACAGCATCCAAAGCGCAC-3\') ([@B16]). PCR were performed in a final volume of 25 μl containing 1X PCR buffer, 2 mM MgCl~2~, 2 mM dNTPs, 10 pmol of primers, 0.25 U Taq DNA polymerase (Fermentas, UK) and 5 μl of template DNA.

PCR conditions included 30 cycles of ampli-fication under the following conditions: denaturation at 95^°^C for 30 s, annealing at 56^°^C for 1 min, and extension at 72^°^C for 1 min/kb product. Cycling was followed by a final extension at 72^°^C for 10 min. PCR products were resolved on 1.0% agarose gels, stained with ethidium bromide, and photographed with UV illumination. The 100-bp DNA ladder was used to assess PCR product size.

***REP-PCR***

All the isolates were subjected to REP-PCR typing method for finding common REP-types among all of the isolates. The primers used for REP-typing include F: 5\'- IIIGCGCCGICATCAGGC-3\' and R: 5\'-ACGTCTTATCAGGCCTAC- 3\' ([@B17]). Amplification reaction was performed in a final volume of 25μl. The reaction contain 2.5 μl of 10X PCR buffer, 1.25U Taq DNA polymerase (Fermentas, UK), 0.8 μl of 2 mM mixed dNTP,1.5 μl of 25 mM MgCl~2~, 1 μl of 10 pmol of primers and 5 μl of template DNA. Amplification reaction was carried out by thermal cycler (Eppendorf, Germany) with an initial denaturation at 94^°^C for 10 min, followed by 30 cycles of denaturation at 94^°^C for 1 min, annealing at 45^°^C for 1 min, and extension at 72^°^C for 1 min, followed by final extension at 72^°^C for 16 min. Samples (20 µl) of each PCR end-product were analysed on agarose 2% wlv gels.

Results
=======

Tigecycline, being effective against all tested *A. baumannii* isolates (100/100), was the most effective antimicrobial agent with the MIC~50~ = 0.125 µg/ml to MIC~90~ = 2 µg/ml. Resistance rate against doxicycline, minocycline and tetracycline was 18%, 19% and 80%, respectively ([Table 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Totally, 50 % (n =50/100) and 4% (n = 4/100) of all the strains were only resistant to tetracycline and minocycline, respectively. Resistance rates of combinations of tetracycline + minocycline, tetracycline + minocy-cline + doxicycline, tetracycline + doxicycline, and minocycline + doxicycline were 16% (n = 16/100), 13% (n = 13/100), 10% (n = 10/100) and 2% (n = 2/100), respectively. Among the isolates, 4 (n = 4/100; 4%) were sensitive to all the antibiotics used in this study whilst 96 (n = 96/100; 96%) were resis-tant to at least one antibiotic among which 13 (n = 13/96; 13.54%) were resistant to all the antibiotics used in this study. Among the resistant isolates, 36 (n = 36/96; 37.5%) were recovered from ICU, 30 from burns ward (n = 30/96; 31.2%), 20 from internal ward (n = 20/96; 20.8%) and 4(n = 4/96, 4.1%) from surgery ward, respectively. Nearly all tetracycline resistant isolates harbored at least one resistance gene ([Table 3](#T3){ref-type="table"}). *Tet*B was the most frequent encoding gene among tetracycline (n = 78/89; 87.6%), minocycline (n = 11/35; 31.4%) and doxicycline (n = 10/25; 40%) resistant *A. baumannii* isolates ([Table 3](#T3){ref-type="table"}). Coexistences of *tet*A + *tet*B was seen among 1.1% (1 out of 80) of the tetracycline resistant isolates, 31.2% (5 out of 16) of the minocycline resistant and 44.4% (8 out of 18) of the doxicycline resistant *A. baumannii* isolates. According to [Table 3](#T3){ref-type="table"} less than 50% of intermediate isolates (intermediate resistance to tetracycline: 44.4%, intermediate resis-tance to minocycline: 31.2% and intermediate re-sistance to doxycycline: 28.5%) harbored *tet* B gene ([Table 3](#T3){ref-type="table"}). REP-PCR showed five clusters A, B, C, D and E with distribution rates of 40% (n = 40/100), 30% (n = 30/100), 10% (n = 10/100), 5% (n = 5/100) and 5% (5/100) among tetracycline resistant *A. baumannii* isolates, respectively. The REP patterns between ten *A. baumannii* isolates could not be dis-tinguished by REP-fingerprinting ([Dendrograme 1](#F1){ref-type="fig"}).

###### 

Antimicrobial susceptibility patterns of tetracycline and related antibiotic against*Acinetobacterbaumannii* isolates

                 MIC vlues   N (%)                              
  -------------- ----------- ------- ----- ---------- --------- ----------
  Tigecycline    0.125-2     0.5     2     100(100)   0         0
  Tetracycline   0.125-512   32      512   11 (11%)   9 (9%)    80 (80%)
  Minocycline    0.125-512   16      32    65 (65)    16 (16)   19(19)
  Doxicycline    0.125-512   16      32    75 (75)    7 (7)     18 (18)

###### 

MIC value of antibiotics against *Acinetobacterbaumannii* isolates

  Antibiotics    MIC diluted (µg/ml)                                                       
  -------------- --------------------- ---- ---- ---- ---- ---- ---- ---- ---- --- --- --- ----
  Tetracycline   1                     0    0    2    4    4    9    19   19   5   2   5   26
  Minocycline    10                    5    5    10   16   19   16   3    5    2   2   3   4
  Doxicycline    8                     14   12   17   9    8    7    2    5    2   2   2   5
  Tigecycline    21                    31   28   10   10   0    0    0    0    0   0   0   0

###### 

Distribution of tetracycline resistance genes among *Acinetobacterbaumannii* isolates regarding different antibiotics

  Antibiotics       Tetracycline n (%)   Minocycline n (%)   Doxicycline n (%)                         
  ----------------- -------------------- ------------------- ------------------- ---------- ---------- ----------
  *tet*A            0 (0)                2 (2.5)             1 (6.25)            3 (15.7)   2 (28.5)   3 (16.6)
  *tet*B            4(44.4)              74 (83.1)           5 (31.2)            6 (31.5)   2 (28.5)   8 (44.4)
  *tet*A + *tet*B   0 (0)                1 (1.2)             5 (31.2)            5 (26.3)   2 (28.5)   4 (22.2)
  None              5 (55.5)             3 (3.7)             5 (31.2)            5 (26.3)   1 (14.2)   3 (16.6)
                                                                                                       

Discussion
==========

The current study can be considered as the first comprehensive study evaluating tetracycline resis-tant *A. baumannii* isolates containing *tet*A and *tet*B resistance determinants in different hospital of Tehran, Iran.

In most clinical practices, tetracyclines are not commonly used as treatments against *A. baumannii* infections due to the lack of data demonstrating their therapeutic efficacy. As a result, tetracycline resistance is not routinely monitored for multi-drug resistant*A. baumannii* and very few data are avail-able on the phenotypic and genotypic characteri-zation of resistance against these bacteriostatic agents among *A. baumannii* strains in Iran. Limited data was previously reported regarding tetracycline resistance among *A. baumannii* strains isolated from burn patients in one educational hospital in Tehran, Iran ([@B6], [@B8], [@B12]). The current study was, however, carried out in different hospitals and different samples.

Most of the *A. baumannii* strains in this study (n = 89/100; 89%) were tentatively classified as tetra-cycline resistant based on an E-test (MIC~50~= 32~µg/ml~ and MIC~90~= 512~µg/ml~). Resistance of the isolates was subsequently confirmed by MIC values of ≥16 μg/ml, which is the proposed clinical breakpoint of CLSI to define resistance against tetracycline, minocycline and doxicycline.
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In this study, like the report from Iran ([@B18]), all of the isolates were sensitive to tigecycline, however, in recent reports from Iran, tetracycline resistant *A. baumannii* isolates was reported from Tehran and Tabriz ([@B15], [@B19]).

Tigecycline is a novel expanded broad-spectrum glycylcycline antibiotic that has a good activity against isolates which are either resistant and/or sensitive to tetracycline, minocycline and doxicyc-line. It seems that the activity of tigecycline is not affected by the tetracycline resistance mechanisms described above. Although resistance to tigecycline is not seen among *A. baumannii* isolates, it has been recently shown that resistance against these antibiotics may exist due to the over expression of AdeABC efflux pump ([@B20]-[@B22]). Both tigecycline highly resistant and sensitive *A. baumannii* have been reported from all over the world ([@B22], [@B23]).

Being highly resistant to tetracycline is common among *A. baumannii*isolates and the result of this study confirmed those data ([@B24]).

Activity of doxycycline in our Iranian *A. baumannii* isolates is in line with the reports from European countries. Mezzatesta and collageous also found that 94% of the isolates were sensitive to doxycycline ([@B22]).

Likewise, Pei *et al* reported high degree of sensitivity to minocycline. We also found mino-cycline has a moderate activity against *A. baumannii* isolates with the sensitivity rate of 65% ([@B25]). The result of Denis *et al* study which showed MDR *A. baumannii*isolates in USA, were susceptible to tigecycline and minocycline is in consistency with our results ([@B26]).

The results, however, suggested a higher prevalence of the *tet*B gene among these clinical isolates (n = 78/89; 87.6%).

These results are consistent with those of Guar-dabassi *et al*, who found that *tet*A and *tet*B are the genes responsible for tetracycline resistance ([@B27]).

The results of this study, therefore, supports these data, since the *tet*A gene was identified in the strains resistant to tetracycline but not in those resistant to minocycline, whilst the gene was not found in the strains resistant to both antibiotics ([@B28]). These strains may possess the *tet*B determinant, which would confer with the resistance to both antibiotics. The genes *tet*A and*tet* B were not detected in 22 clinical isolates of tetracycline resistant *A. baumannii*. Tetracycline resistance in these isolates is probably due to other resistance genes and efflux pumps ([@B29]). REP-patterns could not be distinguished in ten of the isolates studied. Furthermore, only five clusters were identified among the *A. baumannii* isolates. Patterns of resis-tance and distribution of *tet*A and *tet*B genes among different cluster were different. It seems that *A. baumannii* molecular typing via PCR-based methods such as REP, could be beneficial in the differentiation of different strains of *A. baumannii* ([@B30]-[@B33]).

Despite the increased frequency of multidrug resistance among the *A. baumannii* strains from Iran, only a little information exists regarding the antimicrobial resistance of this Gram negative bacillus in Tehran, Iran. The results of this study confirms those of the previous study which was carried out only on burn patients and which reported *tet*A and *tet* B as the most frequent mechanisms of tetracycline resistance among Iranian *A. baumannii* isolates. The identification of *tet*A and *tet*B in this study also confirms the wide geographical distribu-tion of these resistance genes among tetracycline resistant *A. baumannii* strains. The results show that surveillance for multidrug resistant *A. baumannii* should be maintained and careful infection control and cautious use of antibiotics must be taken into consideration.
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